Immtech Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 1984-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.immtechpharma.com
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 111
- Registration Number
- NCT00803933
- Locations
- 🇨🇬
CDTC Maluku, Gombe, Kinshasa, Congo
🇨🇬Vanga Hospital, Gombe, Kinshasa, Congo
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2008-12-05
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT00802594
- Locations
- 🇦🇴
Laboratory of Reference and Investigation, Viana, ICCT, Bairro Ingombota, Luanda, Angola
🇨🇬Programme National de Lutte contre la Trypanosomiase, Kinshasa, Gombe, Congo
Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00619346
- Locations
- 🇿🇦
Farmovs-Parexel, Bloemfontein, Republic of South Africa, South Africa
Prophylactic Antimalarial Activity of DB289 in Volunteers
- Conditions
- Prophylactic Activity Against Malaria
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 19
- Registration Number
- NCT00408369
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
- Conditions
- Pneumonia, Interstitial Plasma CellPneumocystis Carinii PneumoniaPneumonia, Pneumocystis CariniiHIV Infections
- Interventions
- Drug: Trimethoprim-Sulfamethoxazole (TMP-SMX)
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Immtech Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT00302341
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States